Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imaging and oncologic drug development.

Wafik S El-Deiry1, Caroline C Sigman, Gary J Kelloff

  • 1Department of Medicine (Hematology/Oncology), the Abramson Comprehensive Cancer Center, and the Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. wafik@mail.med.upenn.edu

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|July 11, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomarker-Guided Strategies for Tumor Vasculature: From Imaging Advances to Novel Therapeutic Interventions.

Cancer letters·2026
Same author

Editor's Note: Stat1-dependent Induction of Tumor Necrosis Factor-related Apoptosis-inducing Ligand and the Cell-Surface Death Signaling Pathway by Interferon β in Human Cancer Cells.

Cancer research·2026
Same author

PIM1 expression is prognostic in clear cell renal cell carcinoma and influenced by an IL-6/JAK/STAT axis.

American journal of cancer research·2026
Same author

Editor's Note: Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.

Cancer research·2026
Same author

Editor's Note: Cell Cycle-Dependent and Schedule-Dependent Antitumor Effects of Sorafenib Combined with Radiation.

Cancer research·2026
Same author

Editor's Note: Tumorigenic Conversion of Primary Human Esophageal Epithelial Cells Using Oncogene Combinations in the Absence of Exogenous Ras.

Cancer research·2026
Same journal

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

Molecular imaging techniques like PET scans enhance cancer drug development by providing early response detection. These advanced methods aid in preclinical and clinical studies, accelerating therapeutic progress.

Area of Science:

  • Oncology
  • Medical Imaging
  • Drug Development

Background:

  • Anatomic imaging (CT, MRI) has long supported oncology drug development.
  • Metabolic imaging (FDG-PET) offers earlier cancer therapy response detection.
  • Various imaging modalities are increasingly used in preclinical cancer research.

Purpose of the Study:

  • To highlight the role of molecular imaging in advancing cancer drug development.
  • To discuss the application of imaging technologies in preclinical and clinical settings.
  • To emphasize the collaborative efforts to accelerate progress in cancer therapy.

Main Methods:

  • Utilizing computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET).
  • Employing ultrasound and various optical imaging techniques (bioluminescence, fluorescence, etc.).

Related Experiment Videos

  • Applying molecular imaging probes to visualize drug targets and biomarkers in vivo.

    • Main Results:

    • Imaging provides quantifiable evidence of cancer therapy response.
    • Molecular imaging can noninvasively assess drug targets, distribution, and biomarkers.
    • Imaging accelerates the evaluation of genetic alterations and therapeutic effects in animal models.

    Conclusions:

    • Molecular imaging is crucial for accelerating preclinical and clinical anticancer drug development.
    • Collaborative efforts across academia, industry, and regulatory bodies are essential.
    • Continued advancement in imaging technologies promises improved cancer patient outcomes.